Anemia in Non–Dialysis-Dependent CKD: To Treat or Not to Treat?

American Journal of Kidney Diseases

Volumn 73, Issue 3, 2019, Pages 297-299

  Fishbane, Steven ^a   Ross, Daniel W ^a   Hong, Susana ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ANEMIA; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; DISEASE SEVERITY; DRUG SAFETY; EDITORIAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; NON DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; HEMODIALYSIS;

ANEMIA; CARDIOVASCULAR DISEASES; DARBEPOETIN ALFA; HEMATINICS; HUMANS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85059451050     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2018.11.006     Document Type: Editorial

References (17)

1. McClellan, W., Aronoff, S.L., Bolton, W.K., et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20:9 (2004), 1501–1510.
2. Sarnak, M.J., Tighiouart, H., Manjunath, G., et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol 40:1 (2002), 27–33.
3. Astor, B.C., Coresh, J., Heiss, G., Pettitt, D., Sarnak, M.J., Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 151:2 (2006), 492–500.
4. Penninx, B.W., Pahor, M., Woodman, R.C., Guralnik, J.M., Anemia in old age is associated with increased mortality and hospitalization. J Gerontol A Biol Sci Med Sci 61:5 (2006), 474–479.
5. Nissenson, A.R., Goodnough, L.T., Dubois, R.W., Anemia: not just an innocent bystander?. Arch Intern Med 163:12 (2003), 1400–1404.
6. Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W., Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:2 (1987), 73–78.
7. Hayashi, T., Suzuki, A., Shoji, T., et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:2 (2000), 250–256.
8. Keown, P.A., Churchill, D.N., Poulin-Costello, M., et al. Dialysis patients treated with epoetin alfa show improved anemia symptoms: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 14:2 (2010), 168–173.
9. Besarab, A., Bolton, W.K., Browne, J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:9 (1998), 584–590.
10. Drüeke, T.B., Locatelli, F., Clyne, N., et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:20 (2006), 2071–2084.
11. Singh, A.K., Szczech, L., Tang, K.L., et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:20 (2006), 2085–2098.
12. Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:21 (2009), 2019–2032.
13. Mc Causland, F.R., Claggett, B., Burdmann, E.A., et al. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 73:3 (2019), 309–315.
14. Fishbane, S., Recombinant human erythropoietin: has treatment reached its full potential?. Semin Dial 19:1 (2006), 1–4.
15. Szczech, L.A., Barnhart, H.X., Inrig, J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:6 (2008), 791–798.
16. Solomon, S.D., Uno, H., Lewis, E.F., et al., Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363:12 (2010), 1146–1155.
17. Provenzano, R., Besarab, A., Wright, S., et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67:6 (2016), 912–924.